Neuraxis, Inc. Files 8-K on Material Agreement & Equity Sales
Ticker: NRXS · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1933567
| Field | Detail |
|---|---|
| Company | Neuraxis, INC (NRXS) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $5 million, $2.38 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
Neuraxis 8-K: Material deal signed, equity sold. Check financials.
AI Summary
Neuraxis, Inc. filed an 8-K on November 15, 2024, reporting on events that occurred on November 9, 2024. The filing indicates the entry into a material definitive agreement and unregistered sales of equity securities. It also includes financial statements and exhibits.
Why It Matters
This filing signals significant corporate activity for Neuraxis, Inc., potentially impacting its financial structure and future operations through new agreements and equity transactions.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can carry inherent risks and require further scrutiny.
Key Numbers
- 001-41775 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-5079684 — I.R.S. Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Neuraxis, Inc. (company) — Registrant
- November 9, 2024 (date) — Earliest event reported
- November 15, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 11611 N. Meridian St , Suite 330 Carmel , IN 46032 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Neuraxis, Inc. on November 9, 2024?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What type of equity securities were sold in the unregistered sale reported in the 8-K?
The filing mentions unregistered sales of equity securities but does not provide specific details on the type of securities.
What are the key items included in the financial statements and exhibits filed with this 8-K?
The filing indicates that financial statements and exhibits are included, but their specific contents are not detailed in the provided text.
When was Neuraxis, Inc. incorporated, and in which state?
Neuraxis, Inc. was incorporated in Delaware.
What is the principal business address of Neuraxis, Inc.?
The principal executive offices are located at 11611 N. Meridian St , Suite 330 Carmel , IN 46032.
Filing Stats: 979 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-11-15 16:15:35
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NRXS NYSE American Indi
- $5 million — gregate purchase price of approximately $5 million (the " Transaction "). To facilitate th
- $2.38 — alue of the Series B Preferred Stock is $2.38 per share. In connection with the SPA
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 216KB
- ex10-2.htm (EX-10.2) — 127KB
- 0001493152-24-046285.txt ( ) — 624KB
- nrxs-20241109.xsd (EX-101.SCH) — 3KB
- nrxs-20241109_lab.xml (EX-101.LAB) — 33KB
- nrxs-20241109_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 15, 2024 NEURAXIS, INC. By: /s/ Brian Carrico Name: Brian Carrico Title: President and Chief Executive Officer